{"nctId":"NCT00791102","briefTitle":"Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)","startDateStruct":{"date":"2010-01"},"conditions":["Allergic Rhinitis"],"count":20,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ASP-1001 nasal spray"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for ASP-1001"]}],"interventions":[{"name":"ASP-1001 nasal spray","otherNames":[]},{"name":"Placebo for ASP-1001","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males and females between 18 and 55 years of age.\n2. History of grass and/or ragweed allergic rhinitis.\n3. Positive skin test to grass and/or ragweed antigen.\n4. Positive response to screening nasal challenge.\n\nExclusion Criteria:\n\n1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.\n2. Pregnant or lactating women.\n3. Upper respiratory infection or sinusitis within 14 days of study start.\n4. Use of nasal steroids, antihistamines in the last 2 weeks.\n5. FEV1\\<80% of predicted at screening for subjects with history of mild asthma\n6. current smokers or recent ex-smokers\n7. Any social or medical condition that, in the opinion of the investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Days","maximumAge":"55 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Sneezing Symptom","description":"Sneezes. The change is calculated by adding the number of sneezes following both antigen challenges minus twice the number of sneezes after the diluent challenge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Nasal Peak Inspiratory Flow Measurements","description":"The value of nasal peak inspiratory flow. The change is calculated by adding the values of nasal peak inspiratory flow following both antigen challenges minus twice the value of nasal peak inspiratory flow after the diluent challenge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":null},{"groupId":"OG001","value":"-30","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Runny Nose Symptom","description":"The nasal symptoms on a scale of 0-3 (0=no symptoms, 1=mild, 2= moderate, 3= severe). The change is calculated by adding the score of runny nose following both antigen challenges minus twice the score of runny nose after the diluent challenge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Stuffy Nose Symptom","description":"The nasal symptoms on a scale of 0-3 (0=no symptoms, 1=mild, 2= moderate, 3= severe). The change is calculated by adding the score of stuffy nose following both antigen challenges minus twice the score of stuffy nose after the diluent challenge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Itching Symptom","description":"The nasal symptoms on a scale of 0-3 (0=no symptoms, 1=mild, 2= moderate, 3= severe). The change is calculated by adding the score of itchy nose following both antigen challenges minus twice the score of itchy nose after the diluent challenge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Nasal Peak Inspiratory Flow Measurements From Before to After Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":null},{"groupId":"OG001","value":"-10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":[]}}}